Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma

Li, Xinying; Tan, Liuchang; Dong, Liwen; Zhang, Wanqi; Shen, Xiaoxiao; Xiao, Lü; Zheng, Hong; Lu, Yuangang

doi:10.3389/fonc.2020.00597

Cited by 31 publications

(40 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, hypoxia is a major problem in cancer treatment ( 170 ). The current novel photodynamic therapy technology mainly relies on ROS to kill cancer cells, but the hypoxic tumor environment limits its therapeutic value ( 171 , 172 ); thus, combinations with ATV may be a solution. Many studies have also revealed that ATV can indeed improve the efficacy of radiotherapy, chemotherapy, and immunotherapy by reducing the rate of oxygen consumption ( 173 , 174 ).…”

Section: Progress On the Use Of Quinoline Antiparasitic Drugs For Treating Cancermentioning

confidence: 99%

Repositioning of Antiparasitic Drugs for Tumor Treatment

Zheng

Liu

et al. 2021

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Drug repositioning is a strategy for identifying new antitumor drugs; this strategy allows existing and approved clinical drugs to be innovatively repurposed to treat tumors. Based on the similarities between parasitic diseases and cancer, recent studies aimed to investigate the efficacy of existing antiparasitic drugs in cancer. In this review, we selected two antihelminthic drugs (macrolides and benzimidazoles) and two antiprotozoal drugs (artemisinin and its derivatives, and quinolines) and summarized the research progresses made to date on the role of these drugs in cancer. Overall, these drugs regulate tumor growth via multiple targets, pathways, and modes of action. These antiparasitic drugs are good candidates for comprehensive, in-depth analyses of tumor occurrence and development. In-depth studies may improve the current tumor diagnoses and treatment regimens. However, for clinical application, current investigations are still insufficient, warranting more comprehensive analyses.

show abstract

Section: Progress On the Use Of Quinoline Antiparasitic Drugs For Treating Cancermentioning

confidence: 99%

Repositioning of Antiparasitic Drugs for Tumor Treatment

Zheng

Liu

et al. 2021

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The results of this study may be considered after further clinical trials in tumor treatment. [34] For aggressive cancers such as melanoma in which chemotherapy and radiotherapy are ineffective, the efficacy of immunoprotective photodynamic therapy (PDT) as an adjuvant in surgery is also being investigated [35], especially since this therapy has been successfully used to treat patients with non-melanoma skin cancer [36], esophageal cancer [37], head and neck cancers [38], breast cancer [39] and lung cancer [40,41]. Towards the development of specialized photosensitizers (PS) for the treatment of pigmented melanomas, nine novel near-infrared (NIR) absorbing photosensitizers based on divalent rubidium compounds have been investigated [35].…”

Section: Photothermal Therapymentioning

confidence: 99%

Treatment of malignant melanoma - a review of the literature

Kluz

Klas

2021

J Educ Health Sport

View full text Add to dashboard Cite

Melanoma is caused by genetic mutations in melanocytes, pigment-producing cells found in the skin, eye, inner ear, and soft meninges. Sun exposure, atypical nevi, previous history of melanoma, and the presence of multiple (≥40) common nevi were found to be associated with an increased risk of melanoma detection (OR: 1. 3; 95% CI: 1. 1-1. 6). Its prevalence is highest among light-skinned populations and in regions of lower latitudes. Significance of family history of melanoma and presence of congenital nevi were excluded. For localized primary melanoma, the dominant prognostic factors for survival are lesion thickness, ulceration, and lymph node involvement Understanding the pathogenesis of melanoma has been crucial in developing new therapeutic approaches. The characterization of oncogenic signaling pathways and interactions has made it possible to identify new targets for clinically effective therapies, such as pathway inhibitors and antibodies to immune checkpoints or the use of phototherapy. In this article we describe the main signaling pathways which are deregulated in melanoma. We also mention how it has become a viable and crucial strategy for melanoma therapy and then thoroughly review the safety, clinical efficacy and progress regarding PDT- promising alternative therapy and the immunotherapies of melanoma in especially advanced metastatic stage basing on published clinical data and registered clinical trials, most of which are in phase III.

show abstract

“…Additionally, technical limitations in PDT are mostly related to the devices through which light can be guided to deep-seated tumors for activating PDT locally. An interesting issue Pharmaceutics 2021, 13, 1032 2 of 25 for further improving PDT is the characterization of the complex mechanisms underlying its therapeutic effects and the potential therapy-induced resistance [4], both aspects being highly dependent on the tumor type, the structure and properties of the PS and on the PDT settings in terms of light wavelength and fluence. Particular aspects characterizing PDT-induced responses in tumor cells have been already documented, connecting the PDT-induced oxidative stress, cell death, survival mechanisms and danger-associated molecular patterns (DAMPs) production and immunity [5][6][7], but a detailed picture of the intra-network connections is still missing.…”

Section: Introductionmentioning

confidence: 99%

Insight into the Web of Stress Responses Triggered at Gene Expression Level by Porphyrin-PDT in HT29 Human Colon Carcinoma Cells

et al. 2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT), a highly targeted therapy with acceptable side effects, has emerged as a promising therapeutic option in oncologic pathology. One of the issues that needs to be addressed is related to the complex network of cellular responses developed by tumor cells in response to PDT. In this context, this study aims to characterize in vitro the stressors and the corresponding cellular responses triggered by PDT in the human colon carcinoma HT29 cell line, using a new asymmetric porphyrin derivative (P2.2) as a photosensitizer. Besides investigating the ability of P2.2-PDT to reduce the number of viable tumor cells at various P2.2 concentrations and fluences of the activating light, we assessed, using qRT-PCR, the expression levels of 84 genes critically involved in the stress response of PDT-treated cells. Results showed a fluence-dependent decrease of viable tumor cells at 24 h post-PDT, with few cells that seem to escape from PDT. We highlighted following P2.2-PDT the concomitant activation of particular cellular responses to oxidative stress, hypoxia, DNA damage and unfolded protein responses and inflammation. A web of inter-connected stressors was induced by P2.2-PDT, which underlies cell death but also elicits protective mechanisms that may delay tumor cell death or even defend these cells against the deleterious effects of PDT.

show abstract

Susceptibility and Resistance Mechanisms During Photodynamic Therapy of Melanoma

Cited by 31 publications

References 193 publications

Repositioning of Antiparasitic Drugs for Tumor Treatment

Repositioning of Antiparasitic Drugs for Tumor Treatment

Treatment of malignant melanoma - a review of the literature

Insight into the Web of Stress Responses Triggered at Gene Expression Level by Porphyrin-PDT in HT29 Human Colon Carcinoma Cells

Contact Info

Product

Resources

About